Loading
ZNF521 (Zinc finger protein 521) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Oesophageal cancer, Cervical cancer and 5 more.
Transcription factor that can both act as an activator or a repressor depending on the context. Involved in BMP signalling and in the regulation of the immature compartment of the haematopoietic system. Associates with SMADs in response to BMP2 leading to activate transcription of BMP target genes.
Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.24, somatic mutation 0.87). IntOGen calls it a driver in 9 cohorts (5 activating, 4 loss-of-function), covering Cervical Adenocarcinoma, Cutaneous Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Lung Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and others.
In plain words · ZNF521 (Zinc finger protein 521) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Oesophageal cancer, Cervical cancer and 5 more.
ZNF521 (Zinc finger protein 521) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Oesophageal cancer, Cervical cancer and 5 more.
Transcription factor that can both act as an activator or a repressor depending on the context. Involved in BMP signalling and in the regulation of the immature compartment of the haematopoietic system.
No product in this corpus aims at ZNF521 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 2002. Earliest sequence paper UniProt cites for the protein: Tchernev V.T. et al, Mol. Med, 2002, "The Chediak-Higashi protein interacts with SNARE complex and signal transduction proteins". Source.
Sources: HGNC HGNC:24605 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96K83 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000198795 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: oesophageal cancer 0.51, skin cancer 0.55, breast cancer 0.54, lung cancer 0.56, biliary tract cancer 0.50 (GraphQL API, CC0)); IntOGen ZNF521 (driver in 9 cohorts (Act 5, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcription factor that can both act as an activator or a repressor depending on the context. Involved in BMP signalling and in the regulation of the immature compartment of the haematopoietic system. Associates with SMADs in response to BMP2 leading to activate transcription of BMP target genes. Acts as a transcriptional repressor via its interaction with EBF1, a transcription factor involved specification of B-cell lineage; this interaction preventing EBF1 to bind DNA and activate target genes. Location: Nucleus (UniProt). Locus 18q11.2 (HGNC).
Query for this target: (TITLE:"ZNF521" OR ABSTRACT:"ZNF521" OR TITLE:"zinc finger protein 521" OR ABSTRACT:"zinc finger protein 521" OR TITLE:"Zinc finger protein 521" OR ABSTRACT:"Zinc finger protein 521" OR TITLE:"Evi3" OR ABSTRACT:"Evi3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZNF521, not a curated reading list.
Shares Nasopharyngeal carcinoma, Oesophageal cancer, Cervical cancer, IntOGen.
Shares Nasopharyngeal carcinoma, Oesophageal cancer, Skin cancer (all types), Hepatocellular carcinoma.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Hepatocellular carcinoma, IntOGen.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Cervical cancer, IntOGen.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Cervical cancer, IntOGen.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.
Shares Nasopharyngeal carcinoma, IntOGen.